Pasithea Therapeutics Corp. (KTTA) Press Releases https://ir.pasithea.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/pasithea/files/theme/images/logo-sm.png Pasithea Therapeutics Corp. Logo Equisolve Investor Relations Suite <![CDATA[Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial]]> https://ir.pasithea.com/news-events/press-releases/detail/143/pasithea-therapeutics-announces-amendments-to-clinical Tue, 16 Jun 26 07:00:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/143/pasithea-therapeutics-announces-amendments-to-clinical <![CDATA[Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference]]> https://ir.pasithea.com/news-events/press-releases/detail/142/pasithea-therapeutics-announces-exhibit-at-childrens Mon, 15 Jun 26 07:02:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/142/pasithea-therapeutics-announces-exhibit-at-childrens <![CDATA[Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)]]> https://ir.pasithea.com/news-events/press-releases/detail/141/pasithea-therapeutics-announces-orphan-drug-designation-by Tue, 02 Jun 26 07:02:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/141/pasithea-therapeutics-announces-orphan-drug-designation-by <![CDATA[Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer]]> https://ir.pasithea.com/news-events/press-releases/detail/140/pasithea-therapeutics-announces-appointment-of-kartik Mon, 04 May 26 07:01:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/140/pasithea-therapeutics-announces-appointment-of-kartik <![CDATA[Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)]]> https://ir.pasithea.com/news-events/press-releases/detail/139/pasithea-therapeutics-announces-grant-of-rare-pediatric Mon, 20 Apr 26 07:01:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/139/pasithea-therapeutics-announces-grant-of-rare-pediatric <![CDATA[Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity]]> https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track Wed, 01 Apr 26 07:01:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track <![CDATA[Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference]]> https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th Tue, 17 Feb 26 07:01:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th <![CDATA[Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines]]> https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical Tue, 13 Jan 26 07:01:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical <![CDATA[Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock]]> https://ir.pasithea.com/news-events/press-releases/detail/135/pasithea-therapeuticsannounces-closing-of-60-million Tue, 02 Dec 25 07:00:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/135/pasithea-therapeuticsannounces-closing-of-60-million <![CDATA[Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock]]> https://ir.pasithea.com/news-events/press-releases/detail/134/pasithea-therapeuticsannounces-pricing-of-60-million Fri, 28 Nov 25 09:20:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/134/pasithea-therapeuticsannounces-pricing-of-60-million